144 related articles for article (PubMed ID: 38494412)
1. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
Fierro C; Weidenthaler H; Vidojkovic S; Schmidt D; Gafoor Z; Stroukova D; Zwiers S; Müller J; Volkmann A
Vaccine; 2024 Apr; 42(10):2695-2706. PubMed ID: 38494412
[TBL] [Abstract][Full Text] [Related]
2. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
Front Immunol; 2020; 11():598847. PubMed ID: 33542715
[TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses.
Hu WG; Steigerwald R; Kalla M; Volkmann A; Noll D; Nagata LP
Vaccine; 2018 Aug; 36(34):5194-5203. PubMed ID: 30037666
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
[TBL] [Abstract][Full Text] [Related]
6. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
Reed DS; Glass PJ; Bakken RR; Barth JF; Lind CM; da Silva L; Hart MK; Rayner J; Alterson K; Custer M; Dudek J; Owens G; Kamrud KI; Parker MD; Smith J
J Virol; 2014 Oct; 88(20):12077-86. PubMed ID: 25122801
[TBL] [Abstract][Full Text] [Related]
7. Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.
Rico AB; Phillips AT; Schountz T; Jarvis DL; Tjalkens RB; Powers AM; Olson KE
Virology; 2016 Dec; 499():30-39. PubMed ID: 27632563
[TBL] [Abstract][Full Text] [Related]
8. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.
Dupuy LC; Richards MJ; Livingston BD; Hannaman D; Schmaljohn CS
J Immunol Res; 2018; 2018():8521060. PubMed ID: 29967804
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Western, Eastern, and Venezuelan Equine Encephalitis (WEVEE) Virus-Replicon Particle (VRP) Vaccine against WEEV in a Non-Human Primate Animal Model.
Burke CW; Erwin-Cohen RA; Goodson AI; Wilhelmsen C; Edmundson JA; White CE; Glass PJ
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891482
[TBL] [Abstract][Full Text] [Related]
10. Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
Erasmus JH; Seymour RL; Kaelber JT; Kim DY; Leal G; Sherman MB; Frolov I; Chiu W; Weaver SC; Nasar F
J Virol; 2018 Feb; 92(4):. PubMed ID: 29187545
[TBL] [Abstract][Full Text] [Related]
11. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.
Stromberg ZR; Fischer W; Bradfute SB; Kubicek-Sutherland JZ; Hraber P
Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32503232
[TBL] [Abstract][Full Text] [Related]
13. Designing multivalent immunogens for alphavirus vaccine optimization.
Read CM; Plante K; Rafael G; Rossi SL; Braun W; Weaver SC; Schein CH
Virology; 2021 Sep; 561():117-124. PubMed ID: 33823988
[TBL] [Abstract][Full Text] [Related]
14. MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques.
Beddingfield BJ; Plante KS; Plante JA; Weaver SC; Bose S; Krzykwa C; Chirichella N; Redmann RK; Seiler SZ; Dufour J; Blair RV; Endt K; Volkmann A; Maness NJ; Roy CJ
NPJ Vaccines; 2024 Feb; 9(1):47. PubMed ID: 38413593
[TBL] [Abstract][Full Text] [Related]
15. Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV.
Phelps AL; O'Brien LM; Ulaeto DO; Holtsberg FW; Liao GC; Douglas R; Aman MJ; Glass PJ; Moyer CL; Ennis J; Zeitlin L; Nagata LP; Hu WG
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835037
[TBL] [Abstract][Full Text] [Related]
16. Neutralising antibodies for Mayaro virus in Pantanal, Brazil.
Pauvolid-Corrêa A; Juliano RS; Campos Z; Velez J; Nogueira RM; Komar N
Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):125-33. PubMed ID: 25742272
[TBL] [Abstract][Full Text] [Related]
17. Ablation of Programmed -1 Ribosomal Frameshifting in Venezuelan Equine Encephalitis Virus Results in Attenuated Neuropathogenicity.
Kendra JA; de la Fuente C; Brahms A; Woodson C; Bell TM; Chen B; Khan YA; Jacobs JL; Kehn-Hall K; Dinman JD
J Virol; 2017 Feb; 91(3):. PubMed ID: 27852852
[TBL] [Abstract][Full Text] [Related]
18. Comparative pathology study of Venezuelan, eastern, and western equine encephalitis viruses in non-human primates.
Smith DR; Schmaljohn CS; Badger C; Ostrowski K; Zeng X; Grimes SD; Rayner JO
Antiviral Res; 2020 Oct; 182():104875. PubMed ID: 32755661
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
